Jason Katz

Mr. Jason Katz

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
JKJason Katz
Jason Katz
KOKent Owusu
Kent Owusu
INIlisa Nussbaum
Ilisa Nussbaum
RBRachel Beekman
Rachel Beekman
NDNicholas DeFilippo
Nicholas DeFilippo
CMCarolina Maciel
Carolina Maciel
Background: Status epilepticus (SE) carries an exceedingly high mortality and morbidity, often warranting an aggressive therapeutic approach. Recently, the implementation of a ketogenic diet (KD) in adults with refractory and super-refractory SE has been shown to be feasible and effective. Methods: We describe our experience, including the challenges of achieving and maintaining ketosis, in an adult with new onset refractory status epilepticus (NORSE). Case Vignette: A previously healthy 29-year-old woman was admitted with cryptogenic NORSE following a febrile illness; course was complicated by prolonged super-refractory SE. A comprehensive work-up was notable only for mild cerebral spinal fluid (CSF) pleocytosis, elevated nonspecific serum inflammatory markers, and edematous hippocampi with associated diffusion restriction on magnetic resonance imaging (MRI). Repeat CSF testing was normal and serial MRIs demonstrated resolution of edema and diffusion restriction with progressive hippocampal and diffuse atrophy. She required prolonged therapeutic coma with high anesthetic infusion rates, 16 antiseizure drug (ASD) trials, empiric immunosuppression and partial bilateral oophorectomy. Enteral ketogenic formula was started on hospital day 28. However, sustained beta-hydroxybutyrate levels >2 mmol/L were only achieved 37 days later following a comprehensive adjustment of the care plan. KD was challenging to maintain in the intensive care unit (ICU) and was discontinued due to poor nutritional state and pressure ulcers. KD was restarted again in a non-ICU unit facilitating ASD tapering without re-emergence of SE. Discussion: There are inconspicuous carbohydrates in commonly administered medications for SE including antibiotics, electrolyte repletion formulations, different preparations of the same drug (i.e., parenteral, tablet, or suspension) and even solutions used for oral care―all challenging the use of KD in the hospitalized patient. Tailoring comprehensive care and awareness of possible complications of KD are important for the successful implementation and maintenance of ketosis.

30 August 2022 in BMC Pediatrics
Verified
Journal Article
Open access
PDF file
JKJason Katz
Jason Katz
ALAnatalia Labilloy
Anatalia Labilloy
ALAndrew Lee
Andrew Lee
Background: Dysferlinopathy refers to a heterogenous group of autosomal recessive disorders that affect a skeletal muscle protein called dysferlin. These mutations are associated with limb-girdle muscular dystrophy type 2B, Miyoshi myopathy, asymptomatic hyperCKemia, and distal myopathy with anterior tibial onset. Case presentation: A 16 year old female presented with myalgia, weakness and dark urine one week after her second BNT162b2 mRNA (Pfizer) vaccine. Initial serum creatine kinase (CK) was measured at 153,000 IU/L, eventually up-trending to over 200,000 IU/L. However, stable renal function precluded hemodialysis allowing discharge after 10 days of intravenous (IV) hydration and alkaline diuresis. Just two years prior to the current presentation, the patient was hospitalized following Group A Streptococcal pharyngitis infection complicated by rhabdomyolysis. She presented with fatigue, lower extremity weakness, and dark oliguria with CK measuring 984,800 IU/L. IV hydration was attempted however hemodialysis was ultimately required throughout her 24-day hospital stay. Her episode was presumed to be idiopathic and no further work-up was performed at that time. During the patient’s current hospitalization, she reported similar symptomology (myalgias and weakness) following her first quadrivalent Gardasil vaccine at age 11. No hospitalization was required at that time. A comprehensive workup was now initiated while the patient was being treated for her suspected second or third non-exertional, non-traumatic rhabdomyolysis. Rheumatologic, metabolic, infectious, and endocrinologic workup were all unremarkable. Patient eventually had whole exome sequencing performed which revealed a heterozygous pathogenic variant in the DYSF gene (DYSF c.2643 + 1G > A) encoding dysferlin. No clinically significant sequelae occurred thus far. Conclusions: While there have been reports of symptomatic heterozygote carriers of dysferlinopathies, to our knowledge none have been associated with recurrent rhabdomyolysis after immunogenic stimuli. This unique case presentation highlights the importance of a multi-disciplinary care team, the utility of modern whole-exome gene sequencing, and the future challenges of balancing vaccine risk vs benefit.

7 April 2023 in Respiratory Medicine
Verified
Journal Article
Closed access
JKJason Katz
Jason Katz
PSPurav Shah
Purav Shah
CTCesar A. Trillo
Cesar A. Trillo
MAMohammad H. Alshaer
Mohammad H. Alshaer
CPCharles A Peloquin
Charles A Peloquin
JLJorge Lascano
Jorge Lascano

23 July 2025 in Journal of the Society for Cardiovascular Angiography & Interventions
Verified
Journal Article
Open access
JKJason Katz
Jason Katz
AKAravind Kalluri
Aravind Kalluri
MLMarysa Leya
Marysa Leya
PCPaul C. Cremer
Paul C. Cremer
DJDouglas R. Johnston
Douglas R. Johnston
DSDaniel R. Schimmel
Daniel R. Schimmel
Pericardial effusions can occur owing to a variety of reasons such as trauma, infection, autoimmune disease, and malignancy. Cardiac tamponade depends on the rate of fluid accumulation and not solely on the volume of the pericardial effusion. Rapid accumulation of pericardial fluid can lead to impaired cardiac filling and output with hemodynamic consequences, requiring urgent or emergent intervention. Despite initial intervention on patients with cardiac tamponade, recurrence of pericardial effusions has been estimated at approximately 20%, with a mean interval to recurrence of approximately 1 month. Both interventional and surgical techniques have been developed to relieve excess pericardial fluid including pericardiocentesis, surgical pericardiotomy, and percutaneous balloon pericardiotomy (PBP) with the latter 2 generally reserved for recurrent effusions. Rarely, surgical pericardiectomy is pursued. While safety and outcomes data are readily available for both pericardiocentesis and surgical pericardiotomies, PBPs are performed less frequently and at the few medical centers with the necessary expertise. In this case series, we present our center's experience with PBP in the management of recurrent pericardial effusions in 4 different patients. We highlight their comorbidities and corresponding high surgical risk as well as review the technical considerations and outcomes of each patient. Aside from a small pneumothorax managed conservatively, there were no adverse side effects encountered. Balloon pericardiotomy is a safe and effective modality for pericardial effusion drainage in high-risk patients, which can improve patient comfort and hemodynamics.

1 November 2024 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
JKJason Katz
Jason Katz
DSDaniel Schimmel
Daniel Schimmel
MLMarysa Leya
Marysa Leya
ABAlan Betensley
Alan Betensley
MSMrinalini Subramani
Mrinalini Subramani
AAAmbalavanan Arunachalam
Ambalavanan Arunachalam

13 November 2025 in Journal of the Society for Cardiovascular Angiography & Interventions
Verified
Journal Article
Open access
JKJason Katz
Jason Katz
KCKelley Chen
Kelley Chen
MCMichael J. Cuttica
Michael J. Cuttica
RMRuben Mylvaganam
Ruben Mylvaganam
YRYasmin Raza
Yasmin Raza
DSDaniel R. Schimmel
Daniel R. Schimmel
Balloon pulmonary angioplasty (BPA) is the treatment of choice for patients with chronic thromboembolic pulmonary hypertension who cannot receive pulmonary thromboendarterectomy or who have residual pulmonary hypertension after pulmonary thromboendarterectomy. As BPA volume and expertise have increased, significant strides in refining this technique have improved success and minimized complications; yet, minimal literature exists on appropriate complication management. This review summarizes how interventionalists can prevent, recognize, and manage BPA complications effectively. Operators must first focus on appropriate patient and vessel selection. Lower lung zones coupled with ring-like stenoses and web lesions are more favorable. Increased patient age, tortuous or subtotal lesions, and elevated pulmonary vascular resistance (>6 Wood units) portend a higher risk for complications. Vascular perforation can be treated with balloon tamponade, embolization (gelfoam and/or coils), and covered stents. Massive hemoptysis is managed with intubation and single lung ventilation if needed. As shock is predominantly hemorrhagic and/or cardiogenic, first-line therapies include vasopressors, inodilators, pulmonary vasodilators, and volume resuscitation, whereas mechanical support devices are second-line. Although reperfusion lung injury (RLI) is uncommon, it is generally well tolerated and managed with positive pressure ventilation, high-flow oxygen therapy, and diuresis. Acute kidney injury can be reduced by dilution of contrast dye, use of extension catheters, and procedural planning. Utilization of standard, angle-minimizing techniques, avoidance of high-dose cinefluoroscopy, and digital subtraction angiography minimizes radiation dose. In conclusion, most complications can be avoided or managed effectively without major morbidity or mortality by optimal preparation, patient selection, and commitment to a comprehensive BPA program.